Symposium

MRD in AML

Sat. Oct 12, 2019 2:50 PM - 5:00 PM No.1 (Tokyo International Forum, 4F Hall C)

Chairs: Shai Izraeli (Division of Pediatric Hematology and Oncology, Schneider Children's Medical Center of Israel, Israel), Toshihiro Miyamoto (Department of Medicine and Biosystemic Science Kyushu University Faculty of Medicine)

+Add all to schedule

[SY7-1] Measurable/residual disease (MRD) in AML. Recommendations from European LeukemiaNet with the role of flow cytometry in (stem cell) MRD and its relation to molecular approaches

Gerrit J. Schuurhuis, Jeroen JWM Janssen, Jacqueline Cloos (Department of Hematology, Amsterdam University Medical Center, Amsterdam, Netherlands)

[SY7-2] The importance of minimal residual disease analysis using genetic mutations in diagnosis and remission of acute myeloid leukemia

Hiroki Yamaguchi (Department of Hematology, Nippon Medical School)

[SY7-3] Assessment of MRD in standard-risk AML

Robert K Hills¹, Sylvie Freeman², Richard Dillon³, Nigel Russell⁴, David Grimwade³ (1.University of Oxford, Nuffield Dept of Population Health, United Kingdom of Great Britain and Northern Ireland, 2.University of Birmingham, United Kingdom of Great Britain and Northern Ireland, 3.King's College, London, United Kingdom of Great Britain and Northern Ireland, 4.Nottingham University Hospitals, United Kingdom of Great Britain and Northern Ireland)

[SY7-4] Monitoring MRD targeting genetic alterations and aberrant immunophenotypes in pediatric AML

Takashi Taga (Pediatr., Shiga Med. Univ., Otsu, Japan)